Day: December 30, 2024

SAN FRANCISCO, Dec. 30, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. iRhythm’s management is scheduled to present on Monday, January 13, 2025, at 4:30 p.m. Pacific Time/7:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data...

TORONTO, Dec. 30, 2024 (GLOBE NEWSWIRE) — Rivalry Corp. (the “Company” or “Rivalry“) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for digital-first players, today announced that, further to its press releases dated November 26, 2024, November 29, 2024 and December 6, 2024, it has completed its non-brokered private placement of units of the Company (the “Units“), at a price of $0.15 per Unit (the “Offering“). The Company issued an aggregate of 22,146,851 Units in connection with the Offering, for aggregate gross proceeds of approximately $3.32 million. The Company intends to use the proceeds from the Offering for corporate development and general working capital purposes. About Rivalry Rivalry Corp. wholly owns and operates Rivalry Limited, a...

HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5 million tranche of the previously announced Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years. Yorkville agreed to advance to FibroBiologics the first $15 million available under the SEPA in three equal tranches...

Bringing Renewable Fuel Production to Pakistan with Sustainable Biomass Refining Solutions VIRGINIA CITY, Nev., Dec. 30, 2024 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced the execution of a binding agreement between Comstock Fuels Corporation (“Comstock Fuels”) and Gresham’s Eastern (Pvt) Ltd (“Gresham’s”), a leading sustainable energy engineering, equipment and construction company based in Pakistan, under which Comstock Fuels agreed to grant Gresham’s exclusive project and site development rights in Pakistan to enable Gresham’s to deploy Comstock Fuels’ proprietary and patented lignocellulosic biomass refining technologies to produce sustainable aviation fuel (“SAF”) and other renewable fuels in Pakistan. Global Market Impact Gresham’s will develop an initial demonstration facility...

Nokia CorporationStock Exchange Release30 December 2024 at 22:30 EET Nokia Corporation: Repurchase of own shares on 30.12.2024 Espoo, Finland – On 30 December 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 872,093 4.29CEUX – –BATE – –AQEU – –TQEX – –Total 872,093 4.29* Rounded to two decimals On 22 November 2024, Nokia announced that its Board of Directors is initiating a share buyback program to offset the dilutive effect of new Nokia shares issued to the shareholders of Infinera Corporation and certain Infinera Corporation share-based incentives. The repurchases in compliance with the Market Abuse Regulation (EU) 596/2014...

MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports. The NOBLE (Nobody Left Behind) Registry (NOBLE) is a global real-world evidence (RWE) study that aims to improve equity of access to state-of-the-art prostate cancer imaging. NOBLE is a collaboration combining the oncology and prostate cancer expertise of the Oncidium foundation as registry sponsor, Telix’s intellectual property, and partnered clinical and operational support. An international network of sites support the registry locally through Principal Investigators...

Geneva, Switzerland, Dec. 30, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced it expects to end the year with a strong balance sheet and a cash position which is projected to be in excess of $85 million by January 3, 2025. The Company’s advancements in post-quantum technology, widely recognized as a key driver of future growth, have positioned SEALSQ as a leader in this transformative sector. As part of its strategic initiatives, SEALSQ recently raised gross proceeds of $60 million through multiple registered direct offerings. This includes a $10 million registered direct offering announced on December 12, 2024, and an additional...